Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Our Company > Partnerships and Relationships

Partnerships and Relationships

Our business model focuses on building a diversified portfolio of late-stage drugs, primarily in the field of oncology, through acquisition and partnerships, rather than through in-house drug discovery.

We then bring those drugs through the development process, and make them available to patients, worldwide, through our in-house commercial sales organization.

We establish strategic alliances with leading research institutions and biotechnology and pharmaceutical companies, represented by the list below, to leverage our respective strengths, mitigate risks inherent in the drug development process, develop potential best-in-class novel drugs and accelerate drug development timelines.

Ligand PhamaServier Canada

Servier CanadaMundipharma
Onxeo
CASI Pharmaceuticals

Dr.Reddy's LaboratoriesBiogen IdecArbutus Biopharma
Bayer
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Partnering for Success

Spectrum recently formed the following strategic partnerships:

Thermo Fisher Scientific

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific
See press release >

MD Anderson Cancer Center

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
See press release >

Servier Canada

Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada
See press release >

Mundipharma

Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
See press release >

CASI Pharmaceuticals

Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs.
See press release >

Ligand Pharmaceuticals

Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-enabledTM Melphalan.  Product candidate is being investigated as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
See press release >

Hanmi Pharmaceutical Co., Ltd.

Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting G-CSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals
See press release >

Bayer

Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®. Irrevocable License From Bayer Healthcare Leverages Spectrum's Existing Clinical, Regulatory and Marketing Investments
See press release >